Global Allergy and Asthma Patient Platform App – Urticaria
GLOBAL ALLERGY PATIENT GROUP URTICARIA APP
Often it can make sense for international `umbrella’ patient groups to commission, develop or publicise apps on behalf of national patient organisations.
The Global Allergy and Asthma Patient Platform
Rather than individual local patient groups `reinventing the wheel’ to create apps, it can make sense for this shared need to be addressed by umbrella, international patient organisations. A lot depends on the purpose, mandate and focus of these wider groups.
For example, this is how Austrian-based Global Allergy and Asthma Patient Platform (GAAPP), summarises its global advocacy role:
“empowering the patient and supporting the patient voice so that decision makers in both the public and private sectors, in government and industry will be mindful of patient needs, patient desires and patient rights.” – Tonya A. Winders, President, Global Allergy and Asthma Patient Platform
From policy to practical help
However, this group also looks beyond policy to activities that can make a difference to individual patients. Formed in 2009, it now has 30 patient group members on every continent to share information and best practice.
Following on, their website clearly showcases the app they have created for urticaria patients worldwide. The app is currently in four languages, English, German, Spanish and Portuguese, with the intention of developing it in more languages. It acts as a one-stop shop on support for urticaria (hives), from information on symptoms and treatments, through to practical tools to help individuals to identify possible triggers.
Addressing the unmet need
Lastly, when introducing the app, the global group identifies the key benefits:
“The most important step is to identify the triggers and determine the individual sensitivity threshold. To do that it is essential to run a diary that helps to document the course of the disease. This app will help those affected with it. Fewer relapses or a decrease in the severity of relapses, is already a success.” – Global Allergy and Asthma Patient Platform